Sponsored By:

5 Stocks With Awful Sales Growth — NAVB CTEL HKTV CUR IMMU

The worst picks Portfolio Grader has to offer in this fundamental category

   

This week, these five stocks have the worst ratings in Sales Growth, one of the eight Fundamental Categories on Portfolio Grader.

Navidea Biopharmaceuticals, Inc. (AMEX:NAVB) is focused on the development and commercialization of precision radiopharmaceutical diagnostics for diseases such as cancer. NAVB gets F’s in Equity and Cash Flow as well. The price of NAVB is down 48.3% since the first of the year. For more information, get Portfolio Grader’s complete analysis of NAVB stock.

City Telecom (H.K.) Ltd. (NASDAQ:CTEL) provides fixed telecommunications networks and international telecommunications services for residential and corporate customers. CTEL also gets F’s in Earnings Growth and Operating Margin Growth. For more information, get Portfolio Grader’s complete analysis of CTEL stock.

Hong Kong Television Network Ltd. Sponsored ADR (NASDAQ:HKTV) engages in the provision of multimedia production and contents distribution business, and other multimedia related activities in Hong Kong. HKTV gets F’s in Earnings Growth and Operating Margin Growth as well. For more information, get Portfolio Grader’s complete analysis of HKTV stock.

Neuralstem, Inc. (AMEX:CUR) is a biotherapeutics company utilizing its Human Neural Stem Cell technology to develop cures for diseases of the CNS. CUR also gets F’s in Equity and Cash Flow. For more information, get Portfolio Grader’s complete analysis of CUR stock.

Immunomedics, Inc. (NASDAQ:IMMU) develops, manufactures, and sells diagnostic imaging and therapeutic products. IMMU gets F’s in Earnings Growth, Equity, Cash Flow, and Operating Margin Growth as well. For more information, get Portfolio Grader’s complete analysis of IMMU stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, http://investorplace.com/2013/11/5-stocks-with-awful-sales-growth-navb-ctel-hktv-cur-immu-navb-ctel-hktv-cur-immu-3/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.